| Press Releases

Dr. Tom Zhang of Worldwide Clinical Trials to Present at the 16th Annual Immunogenicity & Bioassay Summit, 17 October 2024

Recent expansion of services and capabilities positions CRO for continued growth to meet demand and pressures of increasingly complex bioanalytical market

RESEARCH TRIANGLE PARK, N.C. – 16 OCTOBER 2024 – Tom Zhang, PhD, Chief Scientific Officer, Large Molecule Bioanalysis, at Worldwide Clinical Trials, a global contract research organization (CRO), will present at the 16th annual Immunogenicity & Bioassay Summit.

On 17 October at 2:30 p.m., Dr. Zhang will deliver a presentation titled “Unlocking the Potential of Bioanalytical Automation: Bridging the Gap between Development and Application.” In his talk, Dr. Zhang will delve into the current state of bioanalytical automation, highlighting its challenges and benefits. He will also discuss Worldwide’s case studies and success stories, providing insights into how automation can improve assay accuracy, precision, and consistency in bioanalytical laboratories.

Valued at USD 3.8 billion in 2024 and projected to reach USD 8.1 billion by 2032 (source), the bioanalytical market is under increasing pressure due to rising regulatory requirements, more complex therapeutic approaches, and the shift toward precision medicine. These changes demand higher standards for data quality, integrity, accelerated timelines, and cost-effective solutions. To address these evolving needs, Worldwide has embraced automation in its bioanalytical workflows, enabling the team to deliver high-quality, consistent results while meeting tight deadlines and optimizing costs, thus setting a new standard in today’s competitive landscape.

“I’m excited to share insights on the transformative potential of bioanalytical automation at the Immunogenicity & Bioassay Summit,” said Dr. Zhang. “By bridging the gap between development and application, we can unlock new levels of data quality and project efficiency in our laboratories, ultimately accelerating drug discovery and development.”

Dr. Zhang joined Worldwide in 2022 when the CRO expanded its service offerings to include large molecule capabilities, which were integrated seamlessly into its preexisting clinical pharmacology and pharmacokinetics business unit, as well as more than 15 years of small molecule capabilities. His role was created strategically to offer specialized bioanalysis consultation for sponsors while optimizing data generation timelines and minimizing project costs. Dr. Zhang also plays a key role in supporting Worldwide’s Bioanalytical Lab.

Read Dr. Zhang’s recent article that discusses the importance of finding ways to streamline and automate laboratory processes when analyzing bioanalytical samples here.

About Worldwide Clinical Trials
Worldwide Clinical Trials (Worldwide) is a full-service global contract research organization (CRO) that works in partnership with biotechnology and pharmaceutical companies to create customized solutions that advance new medications – from discovery to reality. Worldwide’s capabilities include bioanalytical laboratory services, Phase I-IV clinical trials, and post-approval and real-world evidence studies – all powered by an accessible team of clinicians, scientists, and researchers who bring first-hand expertise and a collaborative, personalized approach to each clinical program. Worldwide is therapeutically focused on neuroscience, oncology, rare diseases, and cardiometabolic and inflammatory disease. Its global footprint spans over 60 countries with more than 3,600 team members. For more information, visit www.worldwide.com.

Media Contact:
Jill Mastrangelo
Jill.Mastrangelo@Worldwide.com

Recent Press Releases

Resources

Our extensive collection of scientific articles and papers